Enabling competition between therapeutic alternatives is crucial to lowering costs for PBMs’ clients and patients.

A 2021 Evernorth study confirms that many women with insurance didn’t alter plans to grow their families despite COVID-19.

By sharing her experience, Jillian hopes to encourage others to seek help and feel comfortable discussing their struggles.

Evernorth anticipates a dramatic shift in inflammatory and oncology treatments over the next five years, with dozens of biosimilars in the pipeline.

With demand and utilization expanding, comprehensive clinical support and cost-management strategies are crucial to ensuring accessibility and safeguarding health care budgets.